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Abstract Cytosolic phospholipase A2 (cPLA2) plays a critical
role in various neutrophil functions including the generation of
leukotrienes and platelet-activating factor release. Enzyme
activity is regulated both by translocation to the membrane in
a Ca2+-dependent manner and serine phosphorylation by
members of the mitogen-activated protein kinase (MAPK)
family. In this report, we have investigated the role of
granulocyte/macrophage colony-stimulating factor (GM-CSF)-
mediated signalling pathways in the regulation of cPLA2. GM-
CSF-induced cPLA2 phosphorylation was not affected by
pharmacological inhibition of p38 MAPK, phosphatidylinositol
3-kinase or Src. However, inhibition of extracellular signal-
regulated kinase (ERK) MAPK activation resulted in a partial
inhibition of cPLA2 phosphorylation, revealed in a slower onset
of phosphorylation. A cell line stably transfected with the GM-
CSF receptor was used to further analyze GM-CSF-mediated
cPLA2 phosphorylation. Mutation of tyrosine residues 577 and
612 resulted in a delayed cPLA2 phosphorylation similar to the
pharmacological ERK inhibition. Furthermore, inhibition of p38
MAPK in cells bearing the double mutant Lc577/612 completely
abrogated GM-CSF-induced cPLA2 phosphorylation. We con-
clude that GM-CSF can mediate cPLA2 phosphorylation
through the redundant activation of both p38 and ERK MAP
kinases.
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1. Introduction
Neutrophils perform a critical function in the host defence
against microbial infection. Stimulation of these cells induces
multiple responses, including cell adhesion, migration, secre-
tion, phagocytosis, and the generation of reactive oxygen spe-
cies [1]. However, aberrant activation of these cells is also
implicated in the pathogenesis of a variety of in£ammatory
diseases which are associated with tissue damage [1,2]. There-
fore, neutrophil function is tightly regulated by a variety of
chemoattractants and cytokines acting on these cells through
a wide range of receptors. These receptors include tyrosine
kinase-associated receptors such as the interleukins (IL) IL-
3, IL-5, granulocyte/macrophage colony-stimulating factor
(GM-CSF) family of receptors [3], seven-membrane spanning
receptors such as the N-formyl-methionyl-leucyl-phenylala-
nine (fMLP) and platelet-activating factor (PAF) receptors
[4] and receptors reacting with immune complexes, the Fc
receptors [5]. Optimal activation of neutrophils only occurs
in a ‘primed’ state which is induced by prior stimulation [6].
For example, pre-treatment of neutrophils with GM-CSF
primes the NADPH oxidase for a subsequent challenge with
fMLP while not directly stimulating superoxide production
itself [7,8]. However, very little is yet known about the molec-
ular mechanisms underlying the priming of human neutro-
phils.
Stimulation of neutrophils with GM-CSF results in a rapid
increase in tyrosine phosphorylation of many intracellular
proteins [9^11]. The GM-CSF receptor consists of a ligand
speci¢c K-chain (GM-CSFRK) and a common L-chain (Lc)
that is shared with the receptors for IL-3 and IL-5 [12^16].
The Lc does not bind ligand by itself, but is essential for high-
a⁄nity ligand-binding and signal transduction. Activation of
the receptor results in activation of receptor-associated Janus
kinases and tyrosine phosphorylation of the receptor itself [3].
The phosphorylated tyrosine residues in the receptor then
function as docking sites for other intracellular signalling pro-
teins, that in turn are activated. Several members of the mi-
togen-activated protein kinase (MAPK) family are phosphor-
ylated and activated in response to GM-CSF stimulation,
including extracellular signal-regulated kinases (ERKs) and
the p38 MAP kinase [17^20].
Cytosolic phospholipase A2 (cPLA2) plays an important
role in various neutrophil functions including PAF release
and the production of leukotrienes and prostaglandins
[21,22]. cPLA2 activity results in the release of fatty acids
from the sn2 position of membrane phospholipids. The prod-
ucts of this reaction, preferably arachidonic acid and lyso-
phosphatidylcholine, serve as precursors for the generation
of in£ammatory lipids as prostaglandins, leukotrienes and
PAF [21,22]. Furthermore, arachidonic acid by itself can stim-
ulate the NADPH oxidase system, resulting in superoxide
production both in vitro and in vivo [23,24]. cPLA2 activity
is controlled through multiple mechanisms. cPLA2 contains a
calcium-binding C2 region which upon association with Ca2
results in translocation of the enzyme from the cytosol to the
membrane fraction [25^27]. Importantly, serine phosphory-
lation of the enzyme leads to an increase in speci¢c activity
[26,28,29] and is essential for the agonist-induced activation of
the enzyme [30]. Several reports have analyzed this phosphor-
ylation in vivo and although a role for di¡erent MAPK family
members is suggested, the data appear to be contradictory as
to which MAPK family members are critically mediating this
phosphorylation [31^33]. GM-CSF has also been shown to
induce cPLA2 phosphorylation and an increase in the enzy-
me’s speci¢c activity in vitro, although the mechanism by
which this phosphorylation is established is yet unclear
[34,35]. Using the pharmacological inhibitor of MEK kinase,
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the upstream activator of ERK MAP kinases, we recently
demonstrated a role for these kinases in the serum-treated
zymosan (STZ)-induced PAF release [36]. However, the
STZ-mediated PAF response was only partially inhibited
when neutrophils were ¢rst primed with GM-CSF [36]. This
suggested that GM-CSF may activate other downstream ki-
nases able to short-circuit the requirement of ERK activation.
In this report, we have further investigated the mechanism
by which GM-CSF mediates cPLA2 phosphorylation. Our
results suggest that GM-CSF-induced cPLA2 phosphorylation
proceeds through at least two di¡erent signalling pathways
involving both the ERK and the p38 MAPK members. It
appears that these signalling pathways are redundant explain-
ing the widespread ability of cytokines and chemoattractants
to activate cPLA2.
2. Materials and methods
2.1. Isolation of human neutrophils
Blood was obtained from healthy volunteers from the Red Cross
Blood Bank (Utrecht, The Netherlands). Mixed granulocytes were
isolated from the bu¡y-coat of 500 ml 0.4% (w/v) tri-sodium citrate
(pH 7.4)-treated blood as previously described [37]. In short, mono-
nuclear cells were removed by centrifugation over isotonic Ficoll
(1.077 g/ml) from Pharmacia (Uppsala, Sweden). After lysis of the
erythrocytes in an isotonic NH4Cl solution, neutrophils were washed
and resuspended in incubation bu¡er (20 mM HEPES, 132 mM NaCl,
6 mM KCl, 1 mM MgSO4, 1.2 mM KH2PO4, 5 mM glucose, 1 mM
CaCl2) containing 0.5% human serum albumin (CLB, Amsterdam,
The Netherlands). Neutrophils were incubated for 30 min at 37‡C
before stimulation. In all experiments, a concentration of 106 cells/
ml was used for stimulation.
2.2. Neutrophil and BaF3 cell stimulation
Murine BaF3 cells were cultured in RPMI 1640 media supple-
mented with 8% Hyclone serum (Life Technologies, Breda, The Neth-
erlands) and recombinant mouse IL-3. Cells were stably transfected
with human GM-CSF receptor K-chain (EMBL acc. no. NM_006140)
with or without human Lc wild type (Lc WT), Lc mutant Tyr-577 to
Gln (Lc577), Lc mutant Tyr-612 to Phe (Lc612) or the double mutant
Lc577/612 as described previously [38]. Cells stably transfected with
RasV12 or p110 K227E have also been described previously [39].
Prior to stimulation, BaF3 cells were serum-starved at 5U105 cells
per ml at 37‡C for 4 h. Neutrophils were used directly after isolation
at 5U105 cells per ml. In some experiments, cells were pre-incubated
as described in the legends of the ¢gures with one of the following
inhibitors: LY294002, PD098059, staurosporine, GF109203X or PP1
(all from Biomol, Plymouth, PA, USA), SB203580 (Alexis, Laufel¢n-
gen, Switzerland), 1 ml of cells was stimulated with either recombi-
nant human GM-CSF (10310 M, Genzyme, Boston, MA, USA) or
mouse IL-3 for the time indicated. Then, cells were quickly pelleted
and lysed in 1ULaemmli sample bu¡er.
2.3. Protein separation and Western blotting
Protein samples were separated on sodium dodecyl sulfate^polyac-
rylamide gel electrophoresis (SDS^PAGE) (0.4 M Tris^HCl pH 8.3,
10% acrylamide, 0.06% bis-acrylamide, 0.1% SDS) and transferred to
polyvinylidene di£uoride membranes (Immobilon-P, Millipore). The
membranes were probed with anti-cPLA2 antibodies (#sc-454, Santa-
Cruz, CA, USA) and swine anti-rabbit peroxidase-conjugated anti-
bodies (DAKO, Denmark), following detection by enhanced chemilu-
minescence (ECL, Amersham).
Experiments were repeated at least three times. A representative
blot for each experiment is shown.
3. Results
3.1. Regulation of GM-CSF-induced cPLA2 phosphorylation
cPLA2 is regulated by both Ca2-dependent translocation
and phosphorylation [25^29]. cPLA2 has been shown to be a
substrate for members of the family of MAPKs, and ERK1/
ERK2 and p38 MAPK have been shown to mediate cPLA2
phosphorylation both in vitro and in vivo [28,29,40,41]. GM-
CSF activates several MAPK family members in human neu-
trophils, ERK1/ERK2 and p38 MAPK [19,36]. Furthermore,
upon stimulation of human neutrophils with GM-CSF, a rap-
id phosphorylation of cPLA2 is observed [34,35]. We pre-
treated human neutrophils with several kinase inhibitors to
further investigate the mechanism of GM-CSF-induced
cPLA2 phosphorylation.
Stimulation of human neutrophils with GM-CSF causes
phosphorylation of cPLA2, which results in a lower electro-
phoretic mobility of the enzyme on SDS^PAGE [28]. This
‘shift’ in the enzyme’s mobility is thus indicative for its phos-
phorylation. Indeed, cPLA2 was found to be shifted after 15
min of GM-CSF stimulation (Fig. 1A, control), and this shift
was persistent even after 60 min of GM-CSF stimulation.
Next, we pre-treated resting human neutrophils with the phos-
phatidylinositol 3-kinase (PI-3K) inhibitor LY294002. This
inhibitor has been shown to e¡ectively block PI-3K activity
in human neutrophils at a concentration of 10 WM [42]. Pre-
treatment of cells with 10 WM (or 25 WM) LY294002 had no
e¡ect on the GM-CSF-induced cPLA2 phosphorylation (Fig.
1A). In parallel experiments, this inhibitor was found to in-
hibit fMLP-induced superoxide production (data not shown).
The MEK inhibitor PD098059 has been shown to potently
block GM-CSF-induced ERK1/ERK2 activation in human
neutrophils at a concentration of 50 WM [36]. We observed
a partial inhibition of GM-CSF (10310 M)-induced cPLA2
phosphorylation, upon pre-treatment of the neutrophils with
50 WM PD098059, re£ected in a slower onset of cPLA2 phos-
phorylation (Fig. 1B). However, after 60 min, cPLA2 was
fully phosphorylated even when cells were pre-treated with
PD098059. Finally, we analyzed the role of p38 MAPK in
the GM-CSF-induced phosphorylation of cPLA2, utilizing
the SB203550 inhibitor. GM-CSF has been shown to activate
p38 MAPK in human neutrophils [17]. In these cells,
SB203580 completely blocks the GM-CSF-induced p38
MAPK activation at a concentration of 10 WM. However, at
this concentration, SB203580 had no e¡ect on the GM-CSF-
induced cPLA2 phosphorylation (Fig. 1C). These data suggest
that although the ERK MAP kinases might play a role in the
GM-CSF-induced cPLA2 activation, there are additional sig-
nalling pathways, mediating the phosphorylation of cPLA2.
3.2. cPLA2 is constitutively phosphorylated in
p21Ras(V12)-transfected BaF3 cells
The use of combinations of pharmacological inhibitors can
be toxic for cells. To circumvent this problem, we generated
BaF3 cells stably transfected with either GM-CSFRK alone,
or GM-CSFRK and Lc. Stimulation of BaF3 cells stably
transfected with human GM-CSFRK alone did not result in
an increase in cPLA2 phosphorylation, demonstrating the re-
quirement for the human Lc (data not shown). BaF3 cells
stably transfected with both GM-CSFRK in combination
with human Lc (BaF3-GM-CSFRKL) showed a rapid induc-
tion of cPLA2 phosphorylation upon stimulation with GM-
CSF (10310 M, Fig. 2A), with kinetics similar to GM-CSF-
stimulated neutrophils (Fig. 2B). Although cells were serum-
starved for 4 h prior to stimulation with GM-CSF, they some-
times demonstrated background levels of cPLA2 phosphory-
lation (Fig. 2A). This background level of cPLA2 phosphor-
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ylation varied between the experiments, and probably was a
result of incomplete inactivation of cPLA2 after cytokine
withdrawal from the cells. However, upon GM-CSF stimula-
tion, a clear increase in cPLA2 phosphorylation was observed.
To further correlate ERK activation with cPLA2 phosphor-
ylation, we utilized BaF3 cells stably transfected with consti-
tutively active mutants of either p21Ras (p21RasV12) or PI-
3K (p110 K227E) [39]. In analogy with the inhibitor studies
on human neutrophils, the constitutively active PI-3K mutant
had no e¡ect on GM-CSF-induced cPLA2 phosphorylation
(Fig. 2C). However, we observed constitutive cPLA2 phos-
phorylation in cells transfected with RasV12, suggesting a
downstream target of Ras activation is su⁄cient to regulate
this process (Fig. 2C). Since p21Ras regulates ERK activation
in BaF3 cells, this further supports a role for ERK in medi-
ating cPLA2 phosphorylation. To investigate further the role
of ERK activation in cPLA2 activation, we pre-treated BaF3-
GM-CSFRKL cells with the MEK inhibitor PD098059 before
stimulation with GM-CSF. Inhibition of ERK activation re-
sulted in a delayed cPLA2 activation similar to the slow onset
of cPLA2 activation observed in human neutrophils pre-
treated with this inhibitor (Fig. 2D). However, in analogy
with the cPLA2 activation observed in human neutrophils,
cPLA2 became fully phosphorylated after 15 min of GM-
CSF stimulation (Fig. 2D). These data demonstrate that
GM-CSFR-BaF3 cells stably can be used as a model system
for cPLA2 activation. Furthermore, the use of signalling mu-
tants supports a role for ERK and not PI-3K in mediating
cPLA2 phosphorylation.
3.3. Lc tyrosines 577 and/or 612 are not critical for cPLA2
phosphorylation
We utilized BaF3 cells stably transfected with GM-CSFRK
and mutants of Lc bearing point mutations of tyrosine resi-
dues at position 577 (Lc577), 612 (Lc612) or both (Lc577/612)
to further investigate the role of various signalling pathways
emerging from the receptor in cPLA2 phosphorylation. Pre-
viously, we have shown that these tyrosine residues are critical
in mediating both the activation of the Ras-Raf-MAPK and
the PI-3K-PKB pathways from the GM-CSF receptor [20].
The independent Lc577 or Lc612 mutations showed no alter-
ation in the GM-CSF-induced phosphorylation compared to
wild type receptor (Fig. 3). However, cPLA2 phosphorylation
Fig. 1. E¡ect of kinase inhibitors on cPLA2 activation in human
neutrophils. Human neutrophils were isolated as described and pre-
treated for 20 min with either bu¡er (control) or (A) LY294002 (at
10 WM and 25 WM), (B) PD098059 (at 10 WM and 50 WM) or (C)
SB203580 (at 1 WM and 10 WM). Cells (5U105 cells/ml) were stimu-
lated with recombinant human GM-CSF (10310 M) for the time in-
dicated. Cells were lysed and Western blotting was performed as de-
scribed in Section 2.
Fig. 2. GM-CSF-mediated activation of cPLA2 in human neutrophils and BaF3 cells stably transfected with the GM-CSFRKL. (A) BaF3 cells
were stably transfected with GM-CSFRK and Lc. Cells were serum-starved (at 5U105 cells/ml) for 4 h prior to stimulation with recombinant
human GM-CSF (10310 M) for the time indicated. Cells were lysed and Western blotting was performed as described in Section 2. cPLA2 was
detected using anti-cPLA2 antibody. (B) Human neutrophils were isolated as described and stimulated (5U105 cells/ml) with recombinant hu-
man GM-CSF (10310 M) for the time indicated. Cells were lysed and Western blotting was performed as described in Section 2. cPLA2 was de-
tected using anti-cPLA2 antibody. (C) BaF3 cells stably transfected with either constitutively active p21Ras (RasV12) or constitutively active
PI-3K (p110 K227E), as described in Section 2, or control cells were serum-starved (at 5U105 cells/ml) for 4 h prior to stimulation with mouse
IL-3 (10310 M) for the time indicated. Cells were lysed and Western blotting was performed as described in Section 2. cPLA2 was detected us-
ing anti-cPLA2 antibody. (D) BaF3 cells were stably transfected with GM-CSFRK and Lc. Cells were serum-starved (at 5U105 cells/ml) for 4 h.
Cells were pre-treated with bu¡er or PD098059 (50 WM) for 15 min prior to stimulation with recombinant human GM-CSF (10310 M) for the
time indicated. Cells were lysed and Western blotting was performed as described in Section 2. cPLA2 was detected using anti-cPLA2 antibody.
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was partially inhibited in the double mutant, Lc577/612 cells,
which demonstrated a similar slow onset as seen in the
PD098059-treated human neutrophils (compare with Fig.
1B). As a control, we stimulated the BaF3-Lc577/612 cells
with recombinant mIL-3, which utilizes the endogenous
mouse IL-3 receptor for signal transduction [13]. Stimulation
of BaF3-Lc577/612 with mIL-3 resulted in cPLA2 phosphor-
ylation with kinetics comparable to wild type GM-CSF recep-
tor (Fig. 3). These data suggest that the abrogation of ERK
activation by mutant Lc577/612 results in alterations in cPLA2
phosphorylation similar to those observed in GM-CSF-stimu-
lated human neutrophils, pre-treated with the inhibitor of
ERK activation PD098059. This results in a delayed onset
of activation but does not inhibit GM-CSF-mediated cPLA2
phosphorylation. Thus the e¡ects of PD098059 do not appear
to result from toxicity of the inhibitor, but rather re£ect a
partial defect in cPLA2 phosphorylation.
3.4. Multiple signalling pathways mediate Lc-stimulated cPLA2
phosphorylation
Utilizing the Lc577/612 mutant that no longer activates
ERK and has reduced cPLA2 phosphorylation, we are now
able to analyze the e¡ect of additional inhibition of other
signalling pathways. This strategy avoids the problems asso-
ciated with the addition of multiple pharmacological com-
pounds, which proved toxic to the cells (data not shown).
We examined the additional e¡ect of several kinase inhibitors
on the GM-CSF-induced cPLA2 phosphorylation utilizing the
mutated GM-CSF receptor Lc577/612. Pre-treatment of cells
with the p38 MAPK inhibitor SB203580 (10 WM) completely
inhibited the GM-CSF-induced cPLA2 phosphorylation,
whereas the ERK inhibitor PD098059 had no additional e¡ect
(Fig. 4A, upper panel). Utilizing inhibitors of protein kinase C
(GF109203X) or Src kinase (PP1), we investigated the role of
these kinases in cPLA2 phosphorylation. None of these com-
pounds had an inhibitory e¡ect on the GM-CSF-induced
cPLA2 phosphorylation (Fig. 4A, lower panel). Interestingly,
the PKC inhibitor staurosporine induced cPLA2 phosphory-
lation, even in the absence of GM-CSF stimulation (Fig. 4A,
lower panel). Our results suggest that GM-CSF-induced
cPLA2 phosphorylation can occur through at least two redun-
dant signalling pathways. One regulated through tyrosines 577
and 612 of the receptor, and probably involving ERK MAP
kinases. The other involving the activation of p38 MAPK. As
a control, we used BaF3-Lc577 and BaF3-Lc612 cell lines, pre-
treated with the p38 MAPK inhibitor SB203580 as in these
single point mutants ERKs can still be activated in response
to GM-CSF [20]. In line with our hypothesis, SB203580 did
not inhibit GM-CSF-induced cPLA2 phosphorylation in the
context of a receptor that can still activate ERKs (Fig. 4B)
[20].
4. Discussion
In this report, we show that the phosphorylation of cPLA2
induced by GM-CSF stimulation can be mediated by redun-
dant signalling pathways. Previous reports have shown that
cPLA2 is phosphorylated in response to a variety of stimuli in
human neutrophils including GM-CSF, although there is little
consensus as to the relevant signalling pathways regulating
this process [32^34]. We also observed a rapid and prolonged
phosphorylation of cPLA2 in response to GM-CSF stimula-
tion of human neutrophils (Fig. 1). Furthermore, we demon-
strated that in a model cell line system, stably transfected with
the GM-CSF receptor, GM-CSF causes a similar induction of
cPLA2 phosphorylation (Fig. 2). Members of the MAP kinase
family have been implicated in the phosphorylation of cPLA2
in response to a variety of stimuli [32,33]. GM-CSF is known
to activate a variety of intracellular kinases including PI-3K,
p38 and the ERK1/ERK2 MAP kinases [19,36]. Using phar-
macological inhibitors of these kinases, we found that inhibi-
tion of ERK activation by the MEK inhibitor PD098059 re-
sulted in a partial inhibition of cPLA2 phosphorylation. Upon
stimulation with GM-CSF, cPLA2 was rapidly activated in
the control cells, with up to 90% of total cPLA2 being in
the phosphorylated state after 15 min, whereas in the
PD098059-treated cells, only 50% of total cPLA2 was phos-
Fig. 3. Role of Lc tyrosine residues in the activation of cPLA2.
BaF3 cells were stably transfected with GM-CSFRK and either Lc
WT or mutants thereof, bearing mutations of tyrosine residues at
position 577 (Lc577) or 612 (Lc612), or both (Lc577/612), as indi-
cated. Cells (5U105 cells/ml) were serum-starved for 4 h prior to
stimulation with recombinant human GM-CSF (10310 M) or re-
combinant mouse IL-3 for the time indicated. Cells were lysed and
Western blotting was performed as described in Section 2. cPLA2
was detected using anti-cPLA2 antibody.
Fig. 4. E¡ect of kinase inhibitors on cPLA2 activation by Lc tyro-
sine mutants. (A) BaF3 cells were stably transfected with GM-
CSFRK and Lc577/612. Cells were pre-treated with various kinase
inhibitors as indicated for 20 min before stimulation with recombi-
nant human GM-CSF (10310 M) for the time indicated. The inhibi-
tors used are SB203580 (10 WM), PD098059 (50 WM), GF109203X
(5 WM), staurosporine (100 nM) and PP1 (50 WM). (B) BaF3 cells
were stably transfected with GM-CSFRK and either Lc577 or
Lc612. Cells (5U105/ml) were pre-treated with 10 WM SB203580 for
20 min before stimulation with recombinant human GM-CSF
(10310 M) for the time indicated.
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phorylated. However, after 60 min of GM-CSF stimulation,
also in the PD098059-treated cells, all cPLA2 was in the
phosphorylated state. Furthermore, in BaF3 cells stably trans-
fected with constitutively active p21Ras, cPLA2 was constitu-
tively phosphorylated (Fig. 2). As in these cells ERK activa-
tion is downstream of p21Ras activation, this further
correlates ERK activation with cPLA2 phosphorylation. In-
deed, pre-treatment of the BaF3-GM-CSFRKL cells with the
MEK inhibitor PD098059 resulted in a delayed onset of
cPLA2 phosphorylation similar to the e¡ect observed using
this inhibitor in human neutrophils (Fig. 2). As previously
alluded to, the ERKs are able to directly phosphorylate
cPLA2 in vitro [28], and both p38 and ERK MAPKs have
been reported to mediate cPLA2 phosphorylation in vivo
[32,33]. As GM-CSF activates both p38 and ERKs, and inhi-
bition of either one kinase did not result in complete inhibi-
tion of cPLA2 phosphorylation, we reasoned that both ki-
nases might act redundantly in phosphorylating cPLA2.
However, treatment of human neutrophils with the combina-
tion of both the MEK inhibitor PD098059 and the p38
MAPK inhibitor SB203580 proved to be toxic for these cells
(data not shown). To circumvent this problem, we utilized
BaF3 cells stably expressing GM-CSFRK and wild type or
tyrosine mutants of human Lc to further investigate this hy-
pothesis. This approach has avoided adding combinations of
potentially toxic or aspeci¢c pharmacological inhibitors. We
have previously shown that mutation of both tyrosine 577 and
tyrosine 612 of human Lc completely blocks ERK1/ERK2
phosphorylation in response to GM-CSF stimulation of
BaF3 cells [20]. Although mutation of single tyrosines in Lc
had only a minor e¡ect on GM-CSF-induced cPLA2 phos-
phorylation, the double mutant, Lc577/612, clearly showed a
partial inhibition of cPLA2 phosphorylation. This inhibition
was comparable to the inhibition observed using the MEK
inhibitor, suggesting that the inhibiting e¡ect of Lc577/612 is
indeed caused by the lack of ERK activation by this mutant
receptor. Stimulation of these BaF3-Lc577/612 with mouse IL-
3 resulted in a rapid cPLA2 phosphorylation comparable to
the phosphorylation observed in the GM-CSF-stimulated
BaF3-Lc WT cells. Thus, the lack of GM-CSF-induced cPLA2
phosphorylation was not the result of an aspeci¢c defect in
signalling in these cells. We treated BaF3-Lc577/612 cells with
various kinase inhibitors to investigate the identity of further
signals regulating cPLA2 phosphorylation. Although inhibi-
tion of PI-3K or Src kinases had no e¡ect, pre-treatment of
these cells with staurosporine had a stimulatory e¡ect on
cPLA2 phosphorylation. We have previously reported that
staurosporine has a priming e¡ect on human eosinophils
and causes an enhancement of the opsonized zymosan-in-
duced respiratory burst [43]. Moreover, it has been reported
that staurosporine augments the arachidonic acid, thrombox-
ane and LTC4 production, which are events downstream of
cPLA2 activation [44,45]. Interestingly, pre-treatment of the
cells with PKC inhibitor GF109203X, which speci¢cally
blocks PKC K, L and Q isoforms, had no e¡ect on cPLA2
phosphorylation. This suggests that staurosporine exerts its
e¡ect through the inhibition of other PKC isoforms or, alter-
natively, causes cPLA2 activation in a manner independent of
PKC inhibition.
In line with our hypothesis that GM-CSF-induced cPLA2
phosphorylation is mediated by both ERK and p38 MAPK
pathways, we observed a complete inhibition of cPLA2 phos-
phorylation when BaF3-Lc577/612 cells were pre-treated with
SB203580. We conclude that upon GM-CSF stimulation,
multiple signalling pathways act in parallel to phosphorylate
cPLA2. One of which is a pathway acting through the activa-
tion of ERK kinases, while an additional pathway involves
the activation of p38 MAPK. It thus appears that the ERK
and p38 MAP kinases have a redundant function in the phos-
phorylation of cPLA2 in vivo. The mechanism by which a
receptor mediates cPLA2 phosphorylation appears to depend
on its ability to activate either one of these kinases. For ex-
ample, TNFK-induced cPLA2 phosphorylation can be com-
pletely blocked using the pharmacological inhibitor SB203580
[33]. We have demonstrated that TNF does not induce ERK
activation in human neutrophils [36], and therefore ERK ac-
tivation cannot play a role in the TNF-induced cPLA2 phos-
phorylation. Similarly, STZ-mediated cPLA2 activation is de-
pendent on the activation of the ERK MAP kinases, as is
STZ-induced PAF release [36]. However, the STZ-mediated
PAF response was only partially inhibited when neutrophils
were ¢rst primed with GM-CSF [36]. Possibly, the GM-CSF-
mediated p38 activation short-circuits the requirement of
ERK activation in cPLA2 phosphorylation.
We conclude that cPLA2 phosphorylation can be mediated
by both p38 and ERK MAP kinases, and the mechanism by
which a receptor mediates cPLA2 phosphorylation ultimately
depends on the ability of a speci¢c receptor to stimulate the
di¡erent MAP kinase family members.
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